<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">THIETHYLPERAZINE MALEATE</span><br/>(thye-eth-il-per9a-zeen)<br/><span class="topboxtradename">Torecan<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">antiemetic</span><br/><b>Prototype: </b>Prochlorperazine<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg tablets; 5 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Piperazine phenothiazine derivative similar to prochlorperazine. Reportedly higher ratio of antiemetic action to tranquilizing
         action than other phenothiazines. Acts directly on chemoreceptor trigger zone as well as the vomiting center of the brain.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effectively controls nausea and vomiting because it is centrally acting.</p>
<h1><a name="uses">Uses</a></h1>
<p>To control nausea and vomiting.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of vertigo.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to phenothiazines; CNS depression or comatose states; IV administration; pregnancy (category X). Safety in
         children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Kidney or liver disease.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Nausea and Vomiting</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/PR/IM</span> 10 mg 13 times/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Examine parenteral solution and administer only if it is clear and colorless.</li>
<li>
            				Note: Patient should be recumbent when drug is being administered IM. Postural hypotension (manifested by weakness, light-headedness,
            faintness) and drowsiness may occur, particularly after initial injection. Advise patient to remain in bed for about 1 h or
            longer, if indicated, and supervise ambulation.
            			
         </li>
<li>Give IM deep into large muscle mass and aspirate hypodermic carefully before injecting drug to avoid inadvertent entry into
            a blood vessel. IV administration is specifically <b><small>CONTRAINDICATED</small>
</b> because it can cause severe hypotension.
         </li>
<li>Store at 15°30° C (59°86° F) away from heat, in light-resistant containers. Store suppositories
            below 25° C (77° F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Drowsiness,</span> dizziness, headache, restlessness, fever, orthostatic hypotension, extrapyramidal symptoms including convulsions. <span class="typehead">Special Senses:</span>
<span class="speceff-common">Dry mouth and nose,</span> blurred vision, tinnitus, sialorrhea with altered taste sensations. <span class="typehead">GI:</span> Cholestatic jaundice. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Additive adverse effects with other <span class="classification">phenothiazines</span>; additive CNS depression with <b>alcohol,</b>
<span class="classification">anixiolytics</span>, <span class="classification">sedative-hypnotics</span>; may increase <b>phenytoin</b> levels; may decrease effectiveness of <b>bromocriptine,</b>
<b>cabergoline.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 1 h PO, PR; 30 min IM. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Patients who have received drug preoperatively may manifest restlessness or depression during anesthesia recovery.</li>
<li>Report immediately onset of extrapyramidal effects: Gait disturbances, difficulty in speaking, muscle spasms, torticollis,
            deviations in eye movements. Reduction in dosage or discontinuation of medication is indicated.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>